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We report a novel strategy to engineer and express stable
and soluble human recombinant polyvalent/polyspecific
fusion proteins. The procedure is based on the use of a central
skeleton of uteroglobin, a small and very soluble covalently
linked homodimeric protein that is very resistant to proteo-
lytic enzymes and to pH variations. Using a human recombi-
nant antibody (scFv) specific for the angiogenesis marker
domain B of fibronectin, interleukin 2, and an scFv able to neu-
tralize tumor necrosis factor-, we expressed various biologi-
cally active uteroglobin fusion proteins. The results demon-
strate the possibility to generate monospecific divalent and
tetravalent antibodies, immunocytokines, and dual specificity
tetravalent antibodies. Furthermore, compared with similar
fusion proteins in which uteroglobin was not used, the use of
uteroglobin improved properties of solubility and stability.
Indeed, in the reported cases it was possible to vacuum dry and
reconstitute the proteins without any aggregation or loss in pro-
tein and biological activity.
The generation of recombinant polyvalent and/or polyspe-
cific fusion proteins for use as components of novel drugs is still
hindered by factors that limit their production, storage, and
use, chief of which are issues related to instability and/or inad-
equate solubility. Here we describe a novel approach based on
the use of uteroglobin (UG)3 as a skeleton for the generation of
polyvalent/polyspecific recombinant proteins. Human UG is a
small (15.8 kDa) globular, nonglycosylated, and homodimeric
secreted protein that was discovered independently by two
groups in the 1960s in rabbit uterus (1, 2), and it is the first
member of a new superfamily of proteins, the so-called Secre-
toglobins (Scgb) (3). UG is present in the blood at a concentra-
tion of about 15 g/ml and is found in urine and in other body
fluids. The UGmonomer is composed of about 70 amino acids,
depending on the species, and is organized in a four -helix
secondary structure; the two subunits are joined in an anti-
parallel fashion by disulfide bridges established between two
highly conserved cysteine residues in amino- and carboxyl-ter-
minal positions (4) (see Fig. 1). The exact functions of UG are
not yet clear, but the protein has been reported to have anti-
inflammatory properties due to its ability to inhibit the soluble
phospholipase A2. Moreover, UG contains a central hydropho-
bic cavity able to accommodate hydrophobicmolecules such as
progesterone, retinol, and prostaglandin D2. Theoretically, this
cavity could be loaded with different types of therapeutic
hydrophobic substances and delivered to targets (for exhaus-
tive reviews on UG, see Refs. 5, 6and references therein).
The high solubility and stability of UG to pH and tempera-
ture variations, its resistance to proteases, and its homodimeric
structure prompted us to consider the protein as a candidate
linker for the generation of polyvalent and polyspecific recom-
binant proteins. We demonstrate here that the use of UG as a
linker could provide a general method for the generation of
covalently linked bivalent and tetravalent antibodies, either
monospecific or bispecific, as well as of different kinds of fusion
proteins, which, comparedwith similar fusion proteins without
UG, possess generally enhanced properties of solubility and sta-
bility, factors that expedite their storage and clinical use.
We describe the use of UG for the production of a bivalent
and tetravalent format of L19, an scFv specific for the angiogen-
esis-associated extra domain B (ED-B) of fibronectin (FN) (7),
of an immunocytokine composed of IL2 and L19, and of a tet-
ravalent dual specificity antibody composed of L19 and the scFv
D2E7, a human antibody able to neutralize TNF- activity (8).
We report and discuss the characterization, properties, and the
biological activity, both in vitro and in vivo, of these molecules.
EXPERIMENTAL PROCEDURES
Human and Mouse UG cDNAs—Human UG cDNA was
obtained by reverse transcription-PCR from normal human
lung RNA using the Titan One-Step reverse transcription-PCR
system (RocheDiagnostics), with primersTI-36 (seeTable 1 for
primers sequences) and TI-18, containing the EcoRI and NotI
restriction sites, respectively. The resulting product was
digested EcoRI/NotI and was ligated into EcoRI/NotI-digested
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pProEX-1 vector (Invitrogen). Mouse UG cDNA sequence,
provided by GenScript Corp. (Piscataway, NJ), was inserted
into the vector pProEX-1.
L19-hUG and L19-mUG cDNAs—From the construct
L19-TNF-, as described previously (9), we amplified by
PCR the signal peptide, the portions encoding for L19, and
the 15 amino acid linker using the primers TI-21 and TI-22
(9, 10). The resulting product was digested HindIII/BamHI
and was ligated into the expression vector pcDNA3.1
(Invitrogen). Human and mouse UGs were amplified by PCR
from the clones described above using the primers TI-23 and
TI-18 for human UG and the primers TI-24 and TI-17 for
mouse UG. The resulting products of PCR were digested
BamHI/NotI and were inserted into BamHI/NotI-digested
pcDNA3.1/L19-linker, to form pcDNA3.1/L19-hUG and
pcDNA3.1/L19-mUG.
L19-mUG-IL2 cDNA—From the construct pcDNA3.1/
L19-mUG (see above), we amplified by PCR the sequence of the
signal peptide, L19, the linker, and mUGminus the stop codon
using the primers TI-11 and TI-53. The obtained sequence was
inserted into HindIII/NotI digested vector pcDNA3.1. We
obtained the sequence encoding for the linker and IL2 by
PCR from the construct pcDNA3.1/L19-IL2 as described in
Carnemolla et al. (11) using the primers TI-58 and TI-59. The
cDNA fragment was inserted into NotI/XbaI-digested
pcDNA3.1/L19-mUG to generate pcDNA3.1/L19-mUG-IL2.
L19-hUG-L19 and L19-mUG-L19 cDNAs—From the con-
struct pcDNA3.1/L19-hUG described above, the cDNA con-
taining the sequences coding for the signal peptide, L19, the
linker, and hUG minus the stop codon was obtained by PCR
using the primers TI-11 and TI-79. To generate the cDNA
sequence linker L19 to append at the 3 site of the construct
described above, we amplified the L19 sequence by PCR from
pcDNA3.1/L19-IL2 (11) using the primers TI-65 and TI-66.
The resulting sequence was then used as a template for another
PCR with the primers TI-68, including the complete linker
sequence, and TI-66. Finally, the sequences composed of Hin-
dIII/NotI-digested signal peptide-L19-linker-hUGand ofNotI/
XbaI-digested linker L19, respectively, were ligated and
inserted into the HindIII/XbaI digested pcDNA3.1 to form
pcDNA3.1/L19-hUG-L19.
For the generation of the construct pcDNA3.1/L19-mUG-
L19, the construct pcDNA3.1/L19-mUG-IL2 described
above was digested with NotI/XbaI to remove the linker and
IL2 sequences. The sequence encoding for linker L19, as
described above, was digested with NotI/XbaI and ligated
together with NotI/XbaI-digested pcDNA3.1/L19-mUG to
generate pcDNA3.1/L19-mUG-L19.
L19-mUG-D2E7 and L19-hUG-D2E7—For the sequence
linker D2E7, we first amplified PCR D2E7 from pcDNA3.
1/D2E7-mUG using the primers TI-75 and TI-74. Subse-
quently, the obtained sequence was amplified with the primers
TI-73, containing the complete linker sequence, andTI-74. The
resulting sequence, encoding for linker-D2E7, was inserted into
NotI/XbaI-digested pcDNA3.1/L19-mUG (see above) to form
pcDNA3.1/L19-mUG-D2E7.
For the generation of L19-hUG-D2E7, the construct pcDNA3.
1/L19-mUG-D2E7 was digested with BamHI/NotI to remove
themUGsequence.HumanUGwas then inserted into the open
vector to generate pcDNA3.1/L19-hUG-D2E7.
Reagents—All the cDNA constructs were used to transform
DH5-competent bacteria cells, and clones were selected in
Luria Bertani broth (LB) with 100 g/ml ampicillin. Clones
were screened by PCR. The plasmid DNAs were purified from
positive clones using the PureLink HiPure Plasmid Filter Max-
iprep kit (Invitrogen), and the DNA sequences were confirmed
by sequencing the DNA on both strands.
All PCRs were performed with high fidelity PWO DNA po-
lymerase (Roche Diagnostics) according to the manufacturer’s
instructions. All restriction enzymes were from Roche Diag-
nostics. All the PCR products and digested cDNA fragments
were purified with the High Pure PCR Purification kit (Roche
Diagnostics). The digested vectors were purified by gel-agarose
and gel extractionwith theQIAquick gel extraction kit (Qiagen,
Hilden, Germany).
The purified constructs, with the exception of pProEX/hUG
and pProEX/mUG, were used to transfect CHO cells (Ameri-
canTissueTypeCultureCollection,Manassas, VA) using Lipo-
fectamine 2000 CD reagent (Invitrogen) according to the man-
ufacturer’s instructions. Transfectomas were grown in RPMI
1640 (Euroclone, Pavia, Italy) supplemented with 10% fetal
bovine serum (Biochrom AG, Berlin, Germany) and 4 mM
TABLE 1
Sequences of the primers used
TI-11 forward 5-TCAAGCTTGTCGACCATGGGCTGGAGCCTGATC-3
TI-17 reverse 5-CGGCGGCCGCTCAGAATCTTAAATCTTGCTTACACAGAGG-3
TI-18 reverse 5-CGGCGGCCGCATGCTAATTACACAGTGAGCTTTGGGC-3
TI-21 forward 5-CCAAGCTTGTCGACCATGGGCTGGAGCCTGATCC-3
TI-22 reverse 5-GAGGATCCGCCGCTGGACGATGAGCCGGAAGAGC-3
TI-23 forward 5-CTGGATCCGAGATCTGCCCGAGCTTTCAGCGTGTCATC-3
TI-24 forward 5-GCGGATCCTCTTCGGACATCTGCCCAGGATTTCTTC-3
TI-36 forward 5-CGGAATTCCAGAGATCTGCCCGAGCTTTCAGCGTGTCATC-3
TI-53 reverse 5-GAGCGGCCGCTCCGAATCTTAA-3
TI-58 forward 5-TAGCGGCCGCCTCTTCCTCATCG-3
TI-59 reverse 5-GGTCTAGAATCAAGTCAGTGTTG-3
TI-65 forward 5-CTCGGGCCCGAGGTGCAGCTGTTGGAG-3
TI-66 reverse 5-CTCTCTAGAACTAGAATTCTTTGATTTCCAC-3
TI-68 forward 5-CTCGCGGCCGCCTCTTCCTCATCGGGTAGTAGCTCTTCCGGCTCATCGTCCAGCGGCGAGGTGCAGCTGTTGGAG-3
TI-73 forward 5-CTCGCGGCCGCCTCTTCCTCATCGGGTAGTAGCTCTTCCGGCTCATCGTCCAGCGGCGAGGTGCAGCTGGTGGAG-3
TI-74 reverse 5-CTCTCTAGATCATCATTTGATTTCCACCTTGGT-3
TI-75 forward 5-CTCGAGGTGCAGCTGGTGGAGTCT-3
TI-79 reverse 5-CTCGCGGCCGCATTACACAGTGAGCTTTGGGCTATTTTTT-3
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L-glutamine (Invitrogen), and selected using 500 g/ml geneti-
cin (G418, Calbiochem).
The supernatants of theG418-resistant cloneswere screened
for the production of the fusion proteins by ELISA. The recom-
binant peptide composed of the type III homology repeat 7B89
(12) was used as antigen for fusion proteins containing L19
antibody and recombinant human TNF- (PeproTech, Rocky
Hill, NJ) for fusion proteins containingD2E7. Rabbit polyclonal
anti-mouse UG or anti-humanUG antibodies (produced in our
laboratory) were used as secondary antibodies, and a peroxi-
dase-conjugated anti-rabbit immunoglobulin G (IgG) poly-
clonal antibody (Pierce) was used as tertiary antibody.
Fusion proteins were immunopurified from the condi-
tioned media of the cells on ED-B (12) or recombinant
hTNF- (PeproTech, Rocky Hill, NJ) conjugated to Sepha-
rose 4B (Amersham Biosciences). Immunopurified proteins
were analyzed in native conditions by fast protein liquid
chromatography on a Superdex200 column (Amersham Bio-
sciences) and by SDS-PAGE (4–12% gradient) under reduc-
ing and nonreducing conditions.
Radioiodination andBiodistribution Experiments Using L19-
UG, L19-UG-L19, and L19-SIP—Proteins were radioiodi-
nated as described previously (13). Purified fusion proteins
were radiolabeled with 125I using the IODO-GEN method
(Pierce). After labeling, the immunoreactivity of the fusion
proteins was more than 90%. 129/SvHsd mice (Harlan Italy,
Udine, Italy) with subcutaneously implanted F9 murine ter-
atocarcinomas were injected intravenously with about 5 g
(4 Ci; 0.148 MBq) of protein in 100 l of saline solution.
Three animals were used for each time point. Mice were killed
at 4, 24, and 48 h after injection. The organs were weighed, and
the radioactivity was counted using a gamma counter. Target-
ing results are expressed as a per-
cent of the injected dose per g of tis-
sue (% ID/g).
In Vivo Treatment of Tumor-
bearing Mice with L19-UG-IL2 and
Assay of TNF- Neutralizing Ac-
tivity of D2E7-containing Fusion
Proteins—The in vitro assay of IL2
biological activity was carried out by
testing the ability of fusion proteins
to induce T-cell proliferation using
CTLL cells (ATCC) as described
previously (14).
TreatmentwithpurifiedL19-UG-
IL2 fusion protein was performed as
described by Carnemolla et al. (11)
in groups of six 129/SvHsd mice
(Harlan Italy, Udine, Italy), each
injected subcutaneously with 3 
106 F9 cells. Six days after grafting
F9 teratocarcinomas into syngeneic
mice, tumors reached a volume of
nearly 0.3 cm3, and three groups of
four animals each were then treated
for 6 days with a daily intravenous
injection in the tail vein of 250,000
units (equivalent) of IL2 as L19-IL2 or L19-UG-IL2. Controls
received saline alone. The tumor volume was determined
with the following formula: (d)2  D  0.52, where d and D
are the short and long dimensions (centimeters) of the
tumor, respectively, measured with calipers (15). Housing,
treatment, and killing of animals followed national legisla-
tive provisions (Italian law no. 116 of 27 January, 1992) for the
protection of animals used for scientific purposes.
The ability of the D2E7-containing fusion proteins to neu-
tralize hTNF- activity was assessed using the cytotoxicity test
on LM fibroblasts (ATCC) as described previously (9, 16). LM
cells were treated with 1 pM recombinant hTNF- (PeproTech,
Rocky Hill, NJ) in the presence of different concentrations of
L19-mUG-D2E7 orD2E7-mUG. The data are expressed as per-
centage of inhibition of TNF- cytotoxicity.
ELISA Procedures for Studying the Reactions of L19 andD2E7
Moieties within L19-UG-D2E7 with the Respective Antigens—
L19-hUG-D2E7 was tested in ELISA against recombinant FN
fragments composed of the type III homology repeats 7B89.
L19-UG was used as control. ELISA plate wells were coated
with 10 g/ml 7B89. After washing with PBS, wells were incu-
bated with L19-UG-D2E7 or L19-UG at concentrations rang-
ing from 0.03 to 20 nM, in 2% bovine serum albumin in PBS. A
rabbit polyclonal anti-UG antibody (produced in our labora-
tory) was used as secondary antibody, and a peroxidase-conju-
gated anti-rabbit IgG polyclonal antibody (Pierce) was used as
tertiary antibody. Similarly, L19-UG-D2E7 was tested against
human TNF- (PeproTech), using D2E7-UG as control (Fig. 4,
D and E).
The ability of L19 and D2E7 moieties within the L19-UG-
D2E7 molecule to simultaneously bind the respective antigens
in solution was assessed by incubating ELISA plate wells coated
FIGURE 1. Central part of the figure depicts the ribbon structure of the oxidized homodimer of UG
(adaptedwithpermission fromRef. 4).A–E show the schemes of the various fusion proteins produced using
UGas a central core. L19 is an scFv specific for the angiogenesis-associated FN isoform, andD2E7 is an scFv able
to neutralize TNF-.
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with 5g/ml humanTNF- (PeproTech) with 0.8 nM L19-UG-
D2E7 in 2%bovine serumalbumin in PBS in the presence of 100
M of ED-B. Bound L19-UG-D2E7 was then detected using the
secondary and tertiary antibodies as described above. As a con-
trol the same experiment was performed using 7B89 as immo-
bilized antigen (Fig. 5A).
The ability of L19 and D2E7 moieties within the L19-UG-
D2E7 molecule to simultaneously bind the respective antigens
in solid phase was evaluated using human TNF- (PeproTech)
as antigen and 10 g/ml L19-UG-
D2E7 as primary antibody. Excess
protein was washed, and 10 g/ml
of 7B89 was added. After removing
excess 7B89, the bound 7B89 was
detected using the anti fibronectin
type III repeat 9 monoclonal anti-
body, HFN 7.1 (ATCC). A peroxi-
dase-conjugated anti-mouse IgG
polyclonal antibody (Pierce) was
used as tertiary antibody (Fig. 5, B
and C). In all ELISAs the peroxidase
activity was visualized using ABTS
(RocheDiagnostics); the plates were
then read at 405 nm using a SPEC-
TRA-MR (Dynex Technologies,
Chantilly, VA).
RESULTS
Fig. 1 shows the ribbon represen-
tation of the molecular structure of
oxidized UG (4). The UGmonomer
structure is composed of four-hel-
ices. The two monomers of human
UGare held together in anti-parallel
fashion by two disulfide bonds
between Cys-3 and Cys-69 and the
other between Cys-3 and Cys-69.
Fig. 1,A–E, depicts the hypothetical
domain structures of the various
fusion proteins containing UG that
we describe here as follows: dimeric
(Fig. 1A) and tetrameric (Fig. 1B)
formats of the scFv L19 (specific for
the ED-B of FN, a marker of angio-
genesis); an immunocytokine com-
posed of L19 and IL2 (Fig. 1C); the
dimeric format of the scFv D2E7 (a
human scFv able to neutralizeTNF-
activity) (Fig. 1D); and a tetravalent
dual specificity antibody composedof
L19 and D2E7 (Fig. 1E).
L19-UG and L19-UG-L19—To
produce the divalent L19, we pre-
pared a cDNA construct composed
of the scFv L19 cDNA connected at
the 3 end to the 5 end of the UG
cDNA, and to produce the tetrava-
lent L19 format, we appended L19
cDNA at both 3 and 5 ends of the UG cDNA. The resulting
L19-UGandL19-UG-L19 constructs (Fig. 2a) were then cloned
into the vector pcDNA3.1 and used to transfect CHO cells
grown in ProCHO5 animal protein-free media (Lonza, Ver-
viers, Belgium) to produce 5–10 mg/liter recombinant protein
that can be efficiently purified either on ED-B (the antigen of
L19) or protein-A affinity chromatography because the variable
heavy region of immunoglobulin chain of L19 belongs to the
subgroup III and thus contains protein A-binding sites (7, 17).
FIGURE 2. a, scheme of the cDNA constructs of L19-UG (left) and L19-UG-L19 (right). Sp, signal peptide
sequence. b, size exclusion chromatography profiles (Superdex 200) and SDS-PAGE analysis of the purified
fusion proteins L19-UG (left) and L19-UG-L19 (right). Nonreducing (NR) and reducing (R) conditions, respec-
tively. ST, molecular mass standard. c, size exclusion chromatography profiles of L19-UG and L19-UG-L19
reconstituted in distilled water after vacuum drying. d, comparative biodistribution experiments in F9 terato-
carcinoma-bearingmice of three radioiodinated L19 formats: L19-UG, L19-UG-L19, and L19-SIP. The % ID/g in
the tumor at the indicated times after intravenous injection is shown on the left (mean S.D.). To the right the
tumor to blood ratio of the % ID/g at different times after injection of the radioiodinated proteins are plotted.
VL, variable light region of immunoglobulin; CMV, cytomegalovirus;mAu, milli-absorbance units.
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In SDS-PAGE both purified proteinsmigrate as homodimers
in nonreducing conditions and as monomers in reducing con-
ditions, showing apparent sizes of about 63 and 35 kDa, respec-
tively, for the divalent format and of 124 and 62 kDa, respec-
tively, for the tetravalent format. The apparent size of the
nonreduced divalent format was lower compared with the
expected size of 70 kDa, very likely due to the compact confor-
mation of the nonreduced molecule. In nonreducing condi-
tions both molecules were more than 95% covalently linked
dimers (Fig. 2b). The size exclusion chromatography (SEC) pro-
files of both fusion proteins showed a single peak with a reten-
tion volume corresponding to the molecular mass of the
homodimers and the absence of aggregates (Fig. 2b). Both pro-
teins were soluble in PBS at concentrations over 2 mg/ml, and
after vacuum drying, these proteins could be reconstituted
without any loss and without the formation of aggregates (Fig.
2c). These fusion proteins were generated using both mouse
and human UG, and all the proteins presented identical prop-
erties. Our group has previously reported on a different
covalently linked L19 homodimer obtained using the domain 4
of the constant heavy region of human IgE secretory isoform
(small immune protein (SIP)) (13). This protein radiolabeled
with 131I is now extensively used in phase I/II radioimmuno-
therapy trials (18–20). However, L19-SIP, as well as the scFv
per se, presents a much lower solubility than L19-UG fusion
proteins, and it cannot be reconstituted after vacuum drying
without aggregation and precipita-
tion. To obtain a stable solution of
SIP, it is necessary to keep it at a
concentration not exceeding 0.5 mg
per ml and at a temperature of
80 °C in the presence of stabilizers
such as sucrose or Tween to avoid
the formation of precipitates during
thawing. By contrast, the UG con-
structs can be kept in solution in
PBS at either 20 or 80 °C and
thawed without the formation of
any aggregates. These properties,
together with the possibility to keep
the molecules in the dry state, are of
noteworthy importance for the
storage of agents to be used in ther-
apies in hospitals. We compared
the tumor-targeting performance
of the three radioiodinated L19
homodimers (L19-SIP, L19-UG.
and L19-UG-L19) (Fig. 2d) in 129/
SvHsd mice bearing the syngeneic
F9 teratocarcinoma. As reported
previously, the vasculature of the
teratocarcinoma F9 presents the
accumulation of B-FN (9). Fig. 2d
(left panel) shows the percentage of
injected dose per g of tissue (% ID/g)
in the tumor at different times after
injection of the three radioiodinated
L19 formats. Considering the area
under the curves, L19-UG-L19 performed best, although the
L19-UG and the L19-SIP shared a similar area. Fig. 2d (right
panel) shows the ratio of the % ID/g of tumor and of blood for
the three L19 formats as follows: in this case the tumor/blood
ratio was more than two times higher for the two UG formats
than for the SIP format, because of the faster blood clearance
profile of the former. The rapid clearance of molecules used for
immunoradiotherapy is quite important because it limits the
exposure of other organs to radiation.
The ratios of the % ID/g in the tumor versus other organs
were in all cases, at 48 h from injection of the radioiodinated
proteins, greater than 10 (data not shown). The biodistribution
of these L19 formats in other experimental tumor models was
also studied, and in all cases the UG formats performed better
than the SIP format.4
L19-UG-IL2—To demonstrate that UG can also be used to
generate active immunocytokines in the format of stable
covalently linked homodimers, we expressed the immunocyto-
kine L19-UG-IL2. The choice of this immunocytokine was
prompted by the fact that we had previously produced L19-IL2
without UG (11); therefore, this allowed us the opportunity to
compare the properties and the biological activity of the two
molecules and to validate the use of UG for the generation of
4 L. Zardi, manuscript in preparation.
FIGURE 3. A, scheme of the cDNA construct of L19-UG-IL2. Sp, signal peptide sequence. B, SDS-PAGE analysis
(nonreducing (NR) and reducing conditions, respectively); C, size exclusion chromatography profile (Superdex
200) of purified L19-UG-IL2. D, proliferation assay on CTLL cells using [3H]thymidine. Equimolar amounts of
L19-IL2 and L19-UG-IL2 induced identical thymidine incorporation into cells, indicating that the two proteins
share identical IL2 activity. Abs, antibodies. E, tumor growth inhibition of equimolar amounts of L19-IL2 and
L19-UG-IL2 or only saline. Each group consisted of fourmice. Therapy started 7 days after tumor implantation.
Arrows indicate the days of treatment. Tumor size was determined as reported under “Experimental Proce-
dures.” S.E. are indicated. VL, variable light region of immunoglobulin; CMV, cytomegalovirus; mAu, milli-ab-
sorbance units.
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immunocytokines. As is shown in Fig. 3A, the cDNA construct
of L19-UG-IL2 was engineered by recombinant DNA technol-
ogy by ligating the cDNA of the scFv L19 at the 5 end and the
cDNAof IL2 at the 3 end of theUG cDNA. After cloning in the
vector pcDNA3.1, CHO cells were transfected, and the clones
produced roughly 3 mg/liter recombinant protein. In SDS-
PAGE the purified L19-UG-IL2 migrated as a homodimer
(more than 95%) in nonreducing conditions and as a monomer
in reducing conditions at the expected sizes of about 104 and 52
kDa, respectively (Fig. 3B). The SEC profile also showed amain
peak with a retention volume corresponding to the apparent
molecular mass of the homodimer (Fig. 3C). In this case too, it
was possible to vacuum dry and reconstitute the fusion protein
without any loss and without the formation of aggregates (data
not shown). On the contrary, the fusion protein without UG
could not be vacuum-dried and had to be stored at80 °Cwith
stabilizers to prevent the formation of precipitates during thaw-
ing; the fusion protein containing UG, on the other hand, could
be kept at 80 °C in PBS without any stabilizer and thawed
without aggregation and/or formation of precipitates.
We compared the in vitro biological activity of IL2 by CTLL
proliferation assay (14). Equimolar amounts of L19-IL2 and
L19-UG-IL2 showed identical IL2 activity (Fig. 3D). We also
compared the in vivo ability of L19-UG-IL2 and L19-IL2 to
inhibit the growth of F9 teratocarcinoma in syngeneic mice.
When the tumors reached a volume of nearly 0.3 cm3, groups
of animals were treated for 6 days
with daily intravenous injections of
250,000 units of IL2 as L19-IL2,
L19-UG-IL2, or saline alone. The
results depicted in Fig. 3E show that
L19-UG-IL2 had an anti-tumor
activity identical to that previously
reported for L19-IL2 (11).
L19-UG-D2E7—We generated a
dual specificity tetravalentmolecule
using the scFv L19 (anti-ED-B) and
the scFv D2E7 (inhibiting TNF-)
with UG as a central skeleton. As is
shown in Fig. 4A, the cDNA con-
struct of L19-UG-D2E7 was pre-
pared by ligating the cDNA of the
scFv L19 and the cDNA of the scFv
D2E7 at the 5 and 3 ends, respec-
tively, of the UG cDNA. This con-
struct was inserted in the vector
pcDNA3.1, and CHO cells were
transfected; the resulting clones
produced about 3 mg/liter recom-
binant protein. As a control, the
fusion protein D2E7-mUG was
obtained with a similar approach
(data not shown). Fig. 4, B–F, shows
the characterization of the purified
dual specificity tetravalentmolecule
L19-UG-D2E7. In SDS-PAGE (Fig.
4B), the purified proteinmigrated as
a homodimer (more than 95%) in
nonreducing conditions, showing the expected mass of about
124 kDa, and as a monomer with a mass of 62 kDa in reducing
conditions. The SEC profile (Fig. 4C) showed a main peak with
a retention volume corresponding to the molecular mass of the
homodimer. In this case, too, it was possible to vacuum dry and
reconstitute the fusion proteinwithout any loss andwithout the
formation of aggregates (Fig. 4C). The immunoreactivity of
L19-UG-D2E7 was tested by ELISA against the two antigens,
the ED-B and TNF-. The results, shown in Fig. 4, D and E,
show that L19-UG and L19-UG-D2E7 reacted equally well with
the ED-B (Fig. 4D), and that D2E7-UG and L19-UG-D2E7
reacted equally well with TNF- (Fig. 4E), thereby demonstrat-
ing that the two scFvs within the L19-UG-D2E7 molecule do
not interfere with each other. The results of an experiment of
TNF- cytotoxicity inhibition on LMcells using L19-UG-D2E7
and D2E7-UG show (Fig. 4F) that the two formats share a sim-
ilar neutralizing ability, again demonstrating that the two anti-
bodies on the same molecule do not interfere with each other.
We also demonstrated that in L19-UG-D2E7 each antibody
canproperly function in either solution or solid phase.Addition
of an excess amount of ED-B (100 nM) to L19-UG-D2E7 in PBS
containing 2% of bovine serum albumin, although abolishing
the reactivity with the immobilized ED-B, revealed no interfer-
ence with the reactivity of the D2E7 moiety with TNF- (Fig.
5A). To demonstrate that each binding domain could also func-
tion independently in solid phase, ELISAwellswere coatedwith
FIGURE 4. A, scheme of the cDNA construct of L19-UG-D2E7. Sp, signal peptide sequence. CMV, cytomegalov-
irus. B, SDS-PAGE analysis under nonreducing (NR) and reducing (R) conditions; ST, molecular mass standard.
C, size exclusion chromatography profile (Superdex 200) of purified L19-UG-D2E7 (left panel); size exclusion
chromatography profile (Superdex 200) of purified L19-UG-D2E7 after vacuum drying (right panel). The bind-
ing ability to the antibody-specific antigens was studied in ELISA using different concentrations of D. L19-UG-
D2E7onED-Bof FN (usingL19-UGas control); E, against TNF- (usingdivalentD2E7-UGas control). F, inhibitory
activity of hTNF- cytotoxicity of different concentrations of L19-mUG-D2E7 and D2E7-mUG on LM mouse
fibroblasts treated with 1 pM hTNF-. The mean  S.D. are reported. Abs, antibodies; mAu, milli-absorbance
units.
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TNF- and incubatedwith L19-UG-D2E7.The excess antibody
was washed out, and the FN fragment composed of the type III
repeat 7B89 was then added to the well (Fig. 5, B and C). This
fragment bound to the L19moiety and was then detected using
a monoclonal antibody specific for the FN repeat 9. The results
showed that even when an scFv is bound to the antigen in solid
phase, the other is still free to react with its antigen.
Not only was the specific binding ability preserved but the
biological activity of the antibodies was as well, as revealed by
the inhibition of theTNF--mediated cytotoxicity experiments
on LM fibroblasts (Fig. 5D). To mimic the targeted delivery of
D2E7 in tissues containing B-FN, the inhibitory activity of L19-
mUG-D2E7 on hTNF- cytotoxicity was evaluated on LM cells
on culture plates pre-coated with the type III repeat 7B89.
D2E7-UG was used as a nontargeted control. After incubation
of cells with the fusion proteins and washing out the excess,
hTNF- was added. In this condition only the L19-UG-D2E7
should have been present on the plates, because it binds to the
FN fragment with which the plates were coated. The results
obtained (Fig. 5D) demonstrate that even when L19 is bound to
the extra domain B, the D2E7 moiety is still able to neutralize
hTNF-.
DISCUSSION
The generation of effective proteins, particularly antibody
derivatives, is beset by a number of problems, chief of which are
the complex production processes
and aggregation and stability issues
arising during storage. Despite vari-
ous attempts to overcome difficul-
ties (21–24), these obstacles remain.
Herewe describe a novel and gen-
erally applicable approach to gener-
ate tetravalent, dual specificity
fusion proteins using UG as a cen-
tral core of themolecules.We found
that, compared with formats in
which UG was not used, the use of
UG as the scaffold enhanced stabil-
ity and solubility of the fusion pro-
teins. Such improvements in these
properties open the possibility to
store them at 4 °C in a vacuum-
dried state. Indeed, using UG as a
central core, we have demonstrated
the possibility to produce various
immunologically and biologically
active, covalently linked fusion pro-
teins, such as divalent and tetrava-
lent scFvs, immunocytokines com-
posed of scFvs and a cytokine, as
well as tetravalent dual specificity
antibodies.
We generated a divalent and tet-
ravalent format of the human scFv
L19, specific for the ED-B contain-
ing isoform of FN (25). FN is a large
glycoprotein that is present both in
plasma and tissues. TheED-B is a 91-amino acid type III homol-
ogy repeat that is inserted in the FN molecule under tissue-
remodeling conditions by preferential alternative splicing of
the primary transcript (25). The ED-B is undetectable in tissues
from healthy adult individuals, but B-FN is abundant in many
aggressive cancers (26–31). The scFv L19 has been shown to
efficiently and selectively localize in tumor blood vessels in ani-
mal models and in patients with cancer following intravenous
injection (13, 15, 18, 32, 33). Thanks to its ability to selectively
accumulate in neoplastic tissues, L19 is currently undergoing
extensive testing in clinical trials for the radioimmunotherapy
of various forms of tumors, being administered as the divalent
format of SIP radiolabeled with 131I (13, 19, 20, 34, 35).
Here we present two novel formats of L19 that seem partic-
ularly suitable for immunoradiotherapy and that present con-
siderable advantages comparedwith the L19 in the scFv and SIP
formats previously used. In fact, these novel L19-UG formats
performed better than L19-SIP in biodistribution experiments
in tumor-bearing mice (Fig. 2d), showing a higher tumor blood
ratio of the % ID/g of tissue. In addition, considering that UG is
an inhibitor of inflammation and fibrosis (36), two important
side effects of radiotherapy, its presence in the radiolabeled
proteinmight help to reduce these unwanted effects.Moreover,
both the divalent and tetravalent UG are much more soluble
than previously used formats; in fact, in PBS, a concentration of
2 mg/ml without any additive can be achieved without observ-
FIGURE 5.A, ELISA using 0.8 nMD2E7-UG-L19 on the ED-B of FN (white bars) or TNF- (dark gray bars) as antigen
(Ag). The reaction was performed with or without 100 M ED-B. B, schematic drawing; C, results of ELISA
performed using TNF- as antigen and L19-UG-D2E7 as primary antibody; after removing the excess antibody
the FN fragment 7B89was addedandwasdetectedusing anantibody specific for the FN repeat 9.D, L19-mUG-
D2E7 bound to the ED-B neutralizes TNF- cytotoxicity (in situ neutralization). The cytotoxic activity of 1 pM
human TNF- was evaluated on LM cells using plates pre-coated with 7B89 and preincubated with different
concentrations (0.01–500 pM) of L19-mUG-D2E7 () or D2E7-mUG (F). After removing unbound antibodies,
hTNF- was inhibited only by L19-mUG-D2E7, because it bound to the ED-B of FN with which the wells were
pre-coated. Abs, antibodies.
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ing any precipitation or aggregation, qualities that would facil-
itate the radioiodination process. We conducted vacuum dry-
ing experiments using both of the L19-UG formats in PBS and
found that it was possible to reconstitute the proteins using
distilled water without any loss of protein, precipitation, or for-
mation of aggregates. On the contrary, the SIP did not possess
these properties, making its clinical use less easy.
We also generated an immunocytokine composed of the scFv
L19 and IL2, and again we demonstrated that this molecule is
active in both the antibody and the cytokine moieties. Our
group previously prepared a UG-free immunocytokine com-
posed of IL2 and L19 and showed that its fusion with L19
enhanced the therapeutic index of the cytokine (11). This
fusion protein is currently being investigated in a multicenter
phase II clinical study in Italy and Germany (37). Here we com-
pared the biological activity of L19-UG-IL2 andL19-IL2 both in
vitro on T-cells and in vivo on an experimental animal model
and obtained identical results (Fig. 3), thereby demonstrating
that UG could be used as a general approach for the generation
of biologically active immunocytokines in the form of stable,
covalently linked homodimers. In addition, in this case also the
inclusion of UG as a scaffold permitted the vacuum drying of
the construct, which was not possible with the immunocyto-
kine without UG. Moreover, given its anti-inflammatory prop-
erties, UG could be used for the generation of immunocyto-
kines with anti-inflammatory activity, such as IL10. We are
currently investigating whether the presence of UG is able to
enhance the anti-inflammatory properties of similar cytokines.
In fact, it has recently been shown that an immunocytokine
made up of the scFv L19 and IL10 selectively accumulates at
sites of arthritis in collagen-induced arthritis experimental ani-
mal models and that it inhibits disease progression (38). The
activity of this anti-inflammatory immunocytokine could be
further enhanced using UG, which, again, per se possesses anti-
inflammatory properties and, in addition, yields a stable
covalently linked homodimer.
To further demonstrate the versatility of this procedure,
we generated a dual specificity tetravalent antibody using the
scFvs L19 and D2E7. D2E7 is a TNF--neutralizing scFv
marketed as a complete IgG under the brand name Humira,
which has been successfully used for the treatment of rheu-
matoid arthritis. The use of the dual specificity, tetravalent
L19-UG-D2E7 fusion protein could afford a novel therapeu-
tic approach, namely the in situ inhibition of TNF-, because
the presence of L19 would prompt the selective accumula-
tion of the fusion protein at the site of disease sites where
D2E7 could explicate its neutralizing activity. This selective
delivery would, in turn, diminish the side effects of anti-
TNF- antibody treatment. This approach and the in situ
inhibition of TNF- could, of course, be performed using the
entire repertoire of proteins able to inhibit TNF-, including
the TNF- receptor (see Ref. 8 and references therein).
Admittedly, all of these hypotheses must be tested in vivo,
but we have demonstrated the possibility to generate a dual
specificity tetravalent molecule composed of an scFv, L19,
which is able to selectively deliver the molecule to the dis-
eased tissue, and by a second scFv that inhibits TNF-, even
when L19 is engaged with its antigen. All of the fusion pro-
teins we have generated displayed optimal solubility proper-
ties and the absence of aggregates. We also show that each
binding and/or biological active moiety could function inde-
pendently without interfering with each other in either solu-
tion or solid phase.
In conclusion, we describe here a flexible and robust pro-
cedure for the generation of fusion proteins suitable for dif-
ferent therapeutic options, namely radioimmunotherapy,
photodynamic, anti-inflammatory, and immunocytokine
therapies, in a very broad range of angiogenesis-associated
pathologies, including cancer and degenerative diseases. In
addition, the UG homodimer contains a central hydrophobic
cavity with a volume adequate to accommodate hydrophobic
molecules such as progesterone, retinol, and prostaglandin
D2. Theoretically, this cavity could be loaded with different
kinds of hydrophobic therapeutic substances and delivered
to targeted organs or tissues. We are currently investigating
such possibilities (6).
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